User Rating 0.0 ★★★★★

Total Usage 0 times

Category Medicine & Tests

Rate each symptom on a scale of 0 (none) to 10 (very severe) based on your experience over the past week.

Q1. How would you describe your overall level of fatigue/tiredness?

None Very severe

Q2. How would you describe your overall level of AS neck, back, or hip pain?

None Very severe

Q3. How would you describe your overall level of pain/swelling in joints other than neck, back, or hips?

None Very severe

Q4. How would you describe your overall level of discomfort from any areas tender to touch or pressure?

None Very severe

Q5. How would you describe your overall level of morning stiffness you have had from the time you wake up?

None Very severe

Q6. How long does your morning stiffness last from the time you wake up?

0 hrs 2+ hrs

BASDAI Score — / 10

Is this tool helpful?

Your feedback helps us improve.

★ ★ ★ ★ ★

About

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated composite metric developed in 1994 at the Royal National Hospital for Rheumatic Diseases, Bath, UK. It quantifies subjective disease burden across six domains: fatigue, spinal pain, peripheral joint pain, enthesitis (localized tenderness), and two dimensions of morning stiffness. The final score is computed on a 0 - 10 continuous scale. A score ≥ 4 is the internationally accepted threshold (ASAS/EULAR guidelines) for classifying disease as active, which is a prerequisite for initiating biologic therapy such as TNF-α inhibitors. Misinterpretation of this threshold can delay treatment escalation or result in unnecessary pharmacological exposure.

This calculator implements the original Garrett et al. formula. Morning stiffness questions (Q₅ and Q₆) are averaged before inclusion, because they measure overlapping constructs. The tool approximates patient-reported outcomes and does not replace clinical assessment. BASDAI does not capture objective inflammation markers such as CRP or MRI findings. For treatment decisions, clinicians combine BASDAI with ASDAS (which incorporates CRP) and physical examination.

Formulas

The BASDAI score is the arithmetic mean of five components. Questions Q₅ (severity of morning stiffness) and Q₆ (duration of morning stiffness) are first averaged to form a single stiffness component, preventing overweighting of stiffness in the composite.

BASDAI = Q₁ + Q₂ + Q₃ + Q₄ + Q₅ + Q₆25

Where each Q_i ∈ [0, 10]:

Q₁ = Fatigue / tiredness level
Q₂ = Axial (spinal) pain intensity
Q₃ = Peripheral joint pain / swelling
Q₄ = Enthesitis (localized tenderness at tendon/ligament insertion points)
Q₅ = Severity of morning stiffness
Q₆ = Duration of morning stiffness (converted to 0 - 10 VAS scale)

The clinical threshold for active disease: BASDAI ≥ 4.0

Reference Data

Score Range	Disease Activity	Clinical Implication	Typical Action
0.0 - 1.9	Low / Inactive	Minimal symptom burden	Continue current management, monitor
2.0 - 3.9	Moderate	Noticeable symptoms, functional impact possible	Optimize NSAIDs, physiotherapy review
4.0 - 5.9	High (Active Disease)	ASAS threshold met for biologic consideration	Evaluate for TNF-α / IL-17 inhibitors
6.0 - 7.9	Very High	Significant disability risk	Escalate biologic therapy, multidisciplinary referral
8.0 - 10.0	Severe	Maximum disease burden	Urgent rheumatology review, consider combination therapy
Related Indices for Comparison
ASDAS-CRP	< 1.3	Inactive disease (includes CRP)	Objective composite measure
ASDAS-CRP	≥ 2.1	High disease activity	Biologic escalation threshold
BASFI	0 - 10	Functional impairment index	Complements BASDAI for disability
BASMI	0 - 10	Spinal mobility index	Objective mobility measurement
CRP Normal	< 5 mg/L	Systemic inflammation marker	Combined with BASDAI for ASDAS
ESR Normal	< 20 mm/hr	Non-specific inflammation	Supports clinical picture
HLA-B27	Positive / Negative	Genetic susceptibility marker	Diagnostic, not activity measure
mSASSS	0 - 72	Radiographic spinal damage	Structural progression tracking
SPARCC MRI	0 - 72	Sacroiliac joint inflammation	Objective imaging-based activity
BAS-G	0 - 10	Global patient assessment	Single-item well-being VAS

Frequently Asked Questions

Questions 5 and 6 both measure morning stiffness - severity and duration respectively. If both entered the formula independently, stiffness would constitute 2 of 6 raw inputs (33%) rather than the intended equal weighting across 5 domains. Averaging them into one component ensures each domain (fatigue, spinal pain, peripheral pain, enthesitis, morning stiffness) contributes exactly 20% to the final score.

A score of 4.0 is the ASAS/EULAR threshold for classifying ankylosing spondylitis as active. Patients scoring ≥ 4.0 on two consecutive occasions at least 4 weeks apart, who have failed at least two NSAIDs over 4 weeks, become eligible for biologic therapy (TNF-α inhibitors or IL-17 inhibitors). A single measurement at 4.0 does not automatically trigger treatment escalation - temporal consistency matters.

No. BASDAI is a patient-reported outcome measure and is inherently subjective. ASAS guidelines recommend combining it with objective markers. The ASDAS (Ankylosing Spondylitis Disease Activity Score) incorporates CRP alongside BASDAI questions and provides a more robust composite. Clinicians also consider BASFI (functional index), imaging (MRI/X-ray), and physical examination before escalating therapy.

The original BASDAI uses a 100mm visual analogue scale (VAS) where patients mark a point between "none" (0mm) and "very severe" (100mm). The measured distance in millimeters is divided by 10 to yield a 0-10 score. This calculator accepts the 0-10 normalized value directly. Increments of 0.1 correspond to 1mm precision on the original VAS, which is the practical measurement resolution.

Yes. BASDAI was originally developed for ankylosing spondylitis (radiographic axSpA) but is now routinely used across the full axial spondyloarthritis spectrum, including nr-axSpA. The ASAS classification criteria and treatment recommendations apply the same BASDAI ≥ 4.0 threshold regardless of radiographic status. However, nr-axSpA patients may have lower BASDAI scores on average due to earlier disease stage.

ASAS recommends reassessment at 12-week intervals for patients on stable therapy, and at 4-week intervals when evaluating response to a new biologic. A clinically meaningful change is typically defined as an improvement of ≥ 2.0 points (absolute) or ≥ 50% relative reduction. Frequent reassessment within days is unreliable due to natural symptom fluctuation.

BASDAI assigns equal weight to all five domains, which may not reflect individual disease phenotypes. A patient with severe isolated enthesitis but no fatigue may score the same as one with moderate symptoms across all domains. The instrument does not capture extra-articular manifestations (uveitis, inflammatory bowel disease, psoriasis). It is also susceptible to psychological factors - patients with comorbid depression tend to report higher scores independent of inflammatory burden.